Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2018 May 20

PMID 29777455

Citations 14

Authors

Rui Liao

De-Wei Li

Cheng-You Du

Ming Li

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Chronic inflammatory response is a risk factor for hepatocarcinogenesis and recurrence. This study aimed to develop a nomogram incorporating the combined albumin-bilirubin (ALBI) and fibrosis-4 (FIB-4) scores and the peritumoral inflammation score (PIS) to predict postoperative recurrence-free survival (RFS) of hepatocellular carcinoma (HCC).

Methods: The prognostic roles of preoperative ALBI and FIB-4 scores for HCC recurrence were investigated, and a nomogram was developed. The predictive ability of the nomogram was compared with the American Joint Commission on Cancer (AJCC) and Barcelona Clinic Liver Cancer (BCLC) staging systems for HCC. Necroinflammatory activity in the peritumoral liver tissues was evaluated by hematoxylin and eosin (H&E) staining.

Results: Combined ALBI and FIB-4 was associated with PIS in the training and validation cohorts (r = 0.342 and 0.473, both P < 0.001), and all of the scores exhibited predictive value for RFS of HCC. The independent predictive factors of RFS such as AFP, tumor number, tumor size, microvascular invasion, PIS, and combined ALBI and FIB-4 were included in the corresponding nomogram. In the training cohort, the C-index of the RFS nomogram was 0.722. ROC analyses showed that the RFS nomogram had a larger AUC (0.739) than the AJCC and BCLC staging systems. These results were verified by the validation cohort.

Conclusions: The proposed nomogram incorporating PIS and combined ALBI and FIB-4 was associated with recurrence for HCC following curative hepatectomy.

Citing Articles

Baseline FIB-4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV-Related Small HCC.

Zeng Z, Han Y, Li W, Chen H, Lin N, Yu Y Cancer Med. 2025; 14(1):e70535.

PMID: 39783856 PMC: 11714144. DOI: 10.1002/cam4.70535.

Clinical Significance of Fibrosis 4 Index in Early-stage Hepatocellular Carcinoma Patients Received Ultrasound-guided Microwave Ablation.

Chen J, Jiang X, Chen Y, Tang H, Zhang Y, Lu Y Appl Biochem Biotechnol. 2024; .

PMID: 39601976 DOI: 10.1007/s12010-024-05108-w.

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.

Kim M, Han J, An J, Kim B, Jin Y, Kim S Clin Mol Hepatol. 2024; 30(Suppl):S5-S105.

PMID: 39159947 PMC: 11493350. DOI: 10.3350/cmh.2024.0506.

The fibrosis-4 index is a prognostic factor for cholangiocarcinoma patients who received immunotherapy.

Zhang Z, Zhang J, Cai M, Huang X, Guo X, Zhu D Front Immunol. 2024; 15:1376590.

PMID: 38799431 PMC: 11116781. DOI: 10.3389/fimmu.2024.1376590.

Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.

Dallio M, Romeo M, Vaia P, Auletta S, Mammone S, Cipullo M World J Gastroenterol. 2024; 30(7):685-704.

PMID: 38515952 PMC: 10950628. DOI: 10.3748/wjg.v30.i7.685.

References

Bruix J, Gores G, Mazzaferro V . Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844-55. PMC: 4337888. DOI: 10.1136/gutjnl-2013-306627. View

Maluccio M, Covey A . Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012; 62(6):394-9. DOI: 10.3322/caac.21161. View

Sherman M . Recurrence of hepatocellular carcinoma. N Engl J Med. 2008; 359(19):2045-7. DOI: 10.1056/NEJMe0807581. View

ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

Zhu X, Zhang J, Zhuang P, Zhu H, Zhang W, Xiong Y . High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008; 26(16):2707-16. DOI: 10.1200/JCO.2007.15.6521. View

Hernandez-Gea V, Toffanin S, Friedman S, Llovet J . Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013; 144(3):512-27. PMC: 3578068. DOI: 10.1053/j.gastro.2013.01.002. View

Jing Y, Liu W, Guo S, Ye F, Fan Q, Yu G . Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk. Oncotarget. 2015; 6(40):42952-62. PMC: 4767483. DOI: 10.18632/oncotarget.5518. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

Shoaei S, Sali S, Karamipour M, Riahi E . Non-invasive histologic markers of liver disease in patients with chronic hepatitis B. Hepat Mon. 2014; 14(2):e14228. PMC: 3950569. DOI: 10.5812/hepatmon.14228. View

10.

Liao R, Wu H, Yi Y, Wang J, Cai X, He H . Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma. J Exp Clin Cancer Res. 2013; 32:22. PMC: 3654985. DOI: 10.1186/1756-9966-32-22. View

11.

Liu P, Hsu C, Hsia C, Lee Y, Su C, Huang Y . Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol. 2015; 64(3):601-8. DOI: 10.1016/j.jhep.2015.10.029. View

12.

Poynard T, Bedossa P . Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997; 4(3):199-208. DOI: 10.1046/j.1365-2893.1997.00141.x. View

13.

Cheong J, Kim D, Hwang S, Yang J, Kim Y, Park Y . Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. Liver Int. 2011; 31(9):1352-8. DOI: 10.1111/j.1478-3231.2011.02570.x. View

14.

Chan A, Kumada T, Toyoda H, Tada T, Chong C, Mo F . Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol. 2016; 31(7):1300-6. DOI: 10.1111/jgh.13291. View

15.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

16.

Liao R, Fu Y, Wang T, Deng Z, Li D, Fan J . Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. Oncotarget. 2016; 8(1):1774-1787. PMC: 5352096. DOI: 10.18632/oncotarget.12152. View

17.

Liao R, Jiang N, Tang Z, Li D, Huang P, Luo S . Systemic and intratumoral balances between monocytes/macrophages and lymphocytes predict prognosis in hepatocellular carcinoma patients after surgery. Oncotarget. 2016; 7(21):30951-61. PMC: 5058730. DOI: 10.18632/oncotarget.9049. View

18.

Yang S, Liu L, Yang S, Liu L, Ren J, Fang X . Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2016; 103(6):716-724. DOI: 10.1002/bjs.10093. View

19.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

20.

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2):200-7. DOI: 10.1016/s0168-8278(02)00360-4. View